Biopharma therapeutics and platform financing activity in Q1 2026 reflected a strengthening IPO market alongside more selective follow-on and PIPE funding conditions. IPO activity accelerated to 10 deals raising $2.2B, up from 7 deals and $1B in Q4 2025, bringing the two-quarter total to 17 IPOs and $3.2B in proceeds, signaling a gradually reopening issuance window. In contrast, follow-on offerings declined to 38 deals and $8.1B from 52 deals and $11.5B, while PIPE financings fell to 42 deals and $2.9B from 49 deals and $4.8B. Despite slower activity, both markets remained important funding sources, with disciplined capital deployment.
Companies with late-stage clinical catalysts, regulatory milestones, and large commercial opportunities drove top financings in Q1 2026. Xenon Pharmaceuticals raised $748M following strong Phase 3 epilepsy data for azetukalner, while Dianthus Therapeutics secured $719M to advance its autoimmune and neuromuscular pipeline led by claseprubart. Praxis Precision Medicines completed a $575M raise tied to multiple NDA submissions and late-stage CNS programs with estimated peak revenue potential exceeding $20B. Vaxcyte raised $633M to support late-stage development and commercialization of VAX 31, targeting the approximately $8B global pneumococcal vaccine market, while Nektar Therapeutics secured $460M to advance its Phase 3 atopic dermatitis program and broader immunology pipeline.
Biopharma Therapeutics and Platforms IPO Activity
Biopharma therapeutics and platform companies saw a notable acceleration in IPO activity in Q1 2026, with 10 IPOs raising $2.2B, compared with 7 IPOs generating $1B in Q4 2025. Across the two quarters, the sector recorded 17 IPOs and $3.2B in total proceeds. The increase in both deal volume and capital indicates confidence, rising average deal sizes, and a gradually reopening IPO market.
Biopharma Therapeutics and Platforms Follow-On Issuances
Biopharma therapeutics and platform companies continued to access the follow-on and common equity markets, although activity moderated in Q1 2026. The sector completed 38 follow-on offerings raising $8.1B, compared with 52 offerings generating $11.5B in Q4 2025, bringing the two-quarter total to 90 transactions and $19.6B. The decline in both deal volume and proceeds suggests capital deployment has become more selective, resulting in fewer, moderately smaller financings.
Biopharma Therapeutics and Platforms PIPE Issuances
Biopharma therapeutics and platform companies continued to rely on private investment in public equity (PIPE) financings over the past two quarters, although activity slowed in Q1 2026. The sector recorded 42 PIPE deals raising $2.9B, down from 49 deals generating $4.8B in Q4 2025, bringing the two-quarter total to 91 transactions and $7.8B. The decline in both deal volume and proceeds indicates that while PIPEs remain an important source of capital and are becoming more selective.
Top Biopharma Therapeutics and Platforms IPO Activity – Q1 2026
Xenon Pharmaceuticals – Common – $747.5M – March 2026
Xenon, a neuroscience-focused biopharma, closed an upsized $748M offering (12.2M shares at $57.00 plus pre-funded warrants), capitalizing on Phase 3 X TOLE2 data showing a 53.2% reduction in monthly seizures versus placebo for lead asset azetukalner, a KV7 potassium channel opener advancing in epilepsy, MDD, and bipolar depression. Proceeds fund the planned NDA submission for focal onset seizures and broader pipeline work. J.P. Morgan, Jefferies, TD Cowen, Stifel, RBC, and William Blair led the deal.
Dianthus Therapeutics – Common – $719M – March 2026
Dianthus, a clinical-stage autoimmune biotech, closed an upsized $719M offering (8.5M shares at $81.00 plus warrants), lifting cash to roughly $1.2B and extending runway into 2030. Lead asset claseprubart, an active C1s inhibitor, anchors a neuromuscular franchise with Phase 3 EMERGE in generalized Myasthenia Gravis (mid 2026 start, backed by positive MaGic Phase 2 data and Orphan Drug Designation), Phase 3 CAPTIVATE in CIDP (interim 2H 2026), and Phase 2 MoMeNtum in MMN (topline Q4 2026), while DNTH212 targets Sjogren’s, SLE, and Dermatomyositis. Jefferies, TD Cowen, Evercore ISI, Stifel, Guggenheim, and William Blair led the deal; Fairmount Funds became the largest shareholder at 7.71%.
Praxis Precision Medicines – Common – $575M – January 2026
Praxis, a CNS-focused biopharma, closed a $575M offering (2.2M shares at $260.00), generating about $621M in net proceeds and lifting pro forma cash to roughly $1.5B with runway into 2028. The raise capitalizes on a major regulatory inflection: NDAs submitted for ulixacaltamide in Essential Tremor (PDUFA January 29, 2027) and relutrigine in SCN2A/SCN8A DEEs (priority review, PDUFA September 27, 2026), both with Breakthrough Therapy Designation, alongside vormatrigine (POWER1 topline Q2 2026) and elsunersen, with combined peak revenue estimates exceeding $20B. Piper Sandler, TD Cowen, Guggenheim, and Truist led the deal.
Vaxcyte – Common – $632.5M – January 2026
Vaxcyte, a clinical-stage vaccine company built on a cell-free protein synthesis platform, priced a $633M offering (12.65M shares at $50.00), generating approximately $602M in net proceeds and bringing total cash to about $2.7B. Proceeds support the BLA pathway for VAX 31, a broad spectrum pneumococcal conjugate vaccine targeting the approximately $8B global PCV market, with three fully enrolled Phase 3 adult trials (OPUS 1, 2, and 3 covering 6,191 adults) reading out from Q4 2026 through H1 2027, plus a fully enrolled VAX 31 infant Phase 2 study and the planned mid 2026 Phase 1 launch of VAX A1 in Group A Strep. Capital also funds commercial readiness, including a completed Lonza manufacturing facility and a custom North Carolina fill finish line.
Nektar Therapeutics – Common – $460M – February 2026
Nektar, a clinical-stage autoimmune and inflammatory disease biotech, closed a $460M offering (7.6M shares at $58.00 plus pre-funded warrants), yielding approximately $432M in net proceeds, supplemented by $44M from its ATM facility. Proceeds fund the Phase 3 ZENITH AD program for lead asset rezpegaldesleukin (REZPEG), a first-in-class regulatory T cell stimulator initiating by July 2026 in moderate to severe atopic dermatitis, on the strength of positive Phase 2b REZOLVE AD and REZOLVE AA readouts in atopic dermatitis and alopecia areata, with an ongoing Phase 2 in Type 1 diabetes and an early-stage TNFR2 program (NKTR 0165) in multiple sclerosis via a UCSF collaboration. Jefferies, TD Cowen, and Piper Sandler led the deal; Nektar followed with an additional $374M raise in April 2026.
Also check out Biopharma Therapeutics and Platforms Venture Funding – Q1 2026 Review
